Calypso Biotech: Novartis Acquiring Calypso: Details About The Deal

Calypso Biotech BV - a leader in developing Interleukin15 (IL-15) targeted therapies - recently announced that it has agreed to be acquired by Novartis AG. And Calypso's shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development milestones of up to $175 million based on the achievement of certain predetermined milestones. The post Novartis Acquiring Calypso: Details About The Deal appeared first on Pulse 2.0.